Compare NAKA & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NAKA | AAPG |
|---|---|---|
| Founded | 2019 | 2009 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 347.4M | 2.9B |
| IPO Year | 2024 | 2025 |
| Metric | NAKA | AAPG |
|---|---|---|
| Price | $0.51 | $30.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $4.50 | ★ $48.50 |
| AVG Volume (30 Days) | ★ 14.1M | 5.1K |
| Earning Date | 11-19-2025 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,980,278.00 | ★ $54,524,554.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2,774.04 | $368.64 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.43 | $16.50 |
| 52 Week High | $34.77 | $48.45 |
| Indicator | NAKA | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 35.16 | 50.39 |
| Support Level | $0.47 | $30.00 |
| Resistance Level | $0.56 | $33.09 |
| Average True Range (ATR) | 0.05 | 0.83 |
| MACD | 0.05 | 0.14 |
| Stochastic Oscillator | 46.03 | 72.07 |
Kindly MD Inc is a holistically focused pain management clinic and healthcare data company. It offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Its specialty outpatient clinical services are offered on a subscription and fee-for-service basis to augment traditional healthcare. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, travel services, and hormone therapy.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.